Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying

The Dow Jones index closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Exicure

• The Trade: Exicure, Inc. XCUR 10% owner DGP Co., Ltd. bought a total of 237,223 shares at an average price of $3.00. To acquire these shares, it cost around $711,669.
• What's Happening: On Sept. 13, Exicure entered into debt-for-equity exchange agreements..
• What Exicure Does: Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss.

Amylyx Pharmaceuticals

• The Trade: Amylyx Pharmaceuticals, Inc. AMLX CFO James M Frates acquired a total of 40,000 shares at an average price of $2.53. To acquire these shares, it cost around $101,368.
• What's Happening: On Aug. 8, Amylyx Pharma posted an in-line quarterly loss.
• What Amylyx Pharmaceuticals Does: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Reneo Pharmaceuticals

• The Trade: Reneo Pharmaceuticals, Inc. RPHM 10% owner Braden Michael Leonard acquired a total of 358,923 shares at an average price of $1.35. The insider spent around $484,344 to buy those shares.
• What's Happening: On Aug. 13, Reneo Pharmaceuticals reported quarterly losses of 16 cents  per share..
• What Reneo Pharmaceuticals Does: Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company.

Read More:

• ‘If You Want Steel, You Do Nucor,’ Says Cramer When Asked About Gerdau